Skip to main content

Advertisement

SpringerLink
Log in

Clostridium difficile infection: Updates in management

  • Review Article
  • Published:
Indian Journal of Gastroenterology Aims and scope Submit manuscript

Abstract

Clostridium difficile was first identified in 1978 as a diarrhea-causing bacterium in humans. In the last three decades, C. difficile infection (CDI) has reached an epidemic state, both in health care and community settings worldwide. There has been substantial progress in the field of CDI, including identification of novel risk factors, presence of CDI in individuals not considered at risk previously, and treatment options including new drugs, monoclonal antibodies, and fecal microbiota transplantation. This review discusses epidemiology, novel and traditional risk factors, and updates in management for CDI.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bartlett JG, Chang TW, Gurwith M, Gorbach SL, Onderdonk AB. Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia. N Engl J Med. 1978;298:531–4.

    Article  CAS  PubMed  Google Scholar 

  2. Miller BA, Chen LF, Sexton DJ, Anderson DJ. Comparison of the burdens of hospital-onset, healthcare facility-associated Clostridium difficile infection and of healthcare-associated infection due to methicillin-resistant Staphylococcus aureus in community hospitals. Infect Control Hosp Epidemiol. 2011;32:387–90.

    Article  PubMed  Google Scholar 

  3. Khanna S, Baddour LM, Huskins WC, et al. The epidemiology of Clostridium difficile infection in children: a population-based study. Clin Infect Dis. 2013;56:1401–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Khanna S, Pardi DS, Aronson SL, et al. The epidemiology of community-acquired Clostridium difficile infection: a population-based study. Am J Gastroenterol. 2012;107:89–95.

    Article  PubMed  Google Scholar 

  5. Khanna S, Pardi DS. Clostridium difficile infection: new insights into management. Mayo Clin Proc. 2012;87:1106–17.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Zilberberg MD, Shorr AF, Kollef MH. Increase in adult Clostridium difficile-related hospitalizations and case-fatality rate, United States, 2000-2005. Emerg Infect Dis. 2008;14:929–31.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Steiner CBM, Weiss A. HCUP projections: Clostridium difficile hospitalizations 2001 to 2013. HCUP projections report #2014-01. Rockville: Agency for Healthcare Research and Quality; 2014.

    Google Scholar 

  8. McDonald LC, Owings M, Jernigan DB. Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003. Emerg Infect Dis. 2006;12:409–15.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Khanna S, Pardi DS. Community-acquired Clostridium difficile infection: an emerging entity. Clin Infect Dis. 2012;55:1741–2.

    Article  PubMed  Google Scholar 

  10. Chitnis AS, Holzbauer SM, Belflower RM, et al. Epidemiology of community-associated Clostridium difficile infection, 2009 through 2011. JAMA Intern Med. 2013;173:1359–67.

    Article  PubMed  Google Scholar 

  11. Allard R, Dascal A, Camara B, Létourneau J, Valiquette L. Community-acquired Clostridium difficile-associated diarrhea, Montréal, 2005-2006: frequency estimates and their validity. Infect Control Hosp Epidemiol. 2011;32:1032–4.

    Article  PubMed  Google Scholar 

  12. Bhattacharya MK, Niyogi SK, Rasaily R, et al. Clinical manifestation of Clostridium difficile enteritis in Calcutta. J Assoc Physicians India. 1991;39:683–4.

    CAS  PubMed  Google Scholar 

  13. Gupta U, Yadav RN. Clostridium difficile in hospital patients. Indian J Med Res. 1985;82:398–401.

    CAS  PubMed  Google Scholar 

  14. Niyogi SK, Bhattacharya SK, Dutta P, et al. Prevalence of Clostridium difficile in hospitalised patients with acute diarrhoea in Calcutta. J Diarrhoeal Dis Res. 1991;9:16–9.

  15. Kaneria MV, Paul S. Incidence of Clostridium difficile associated diarrhoea in a tertiary care hospital. J Assoc Physicians India. 2012;60:26–8.

    PubMed  Google Scholar 

  16. Linsky A, Gupta K, Lawler EV, Fonda JR, Hermos JA. Proton pump inhibitors and risk for recurrent Clostridium difficile infection. Arch Intern Med. 2010;170:772–8.

    Article  PubMed  Google Scholar 

  17. Khanna S, Pardi DS. IBD: poor outcomes after Clostridium difficile infection in IBD. Nat Rev Gastroenterol Hepatol. 2012;9:307–8.

    Article  CAS  PubMed  Google Scholar 

  18. Khanna S, Pardi DS. The growing incidence and severity of Clostridium difficile infection in inpatient and outpatient settings. Expert Rev Gastroenterol Hepatol. 2010;4:409–16.

    Article  PubMed  Google Scholar 

  19. Otten AM, Reid-Smith RJ, Fazil A, Weese JS. Disease transmission model for community-associated Clostridium difficile infection. Epidemiol Infect. 2010;138:907–14.

    Article  CAS  PubMed  Google Scholar 

  20. Tonna I, Welsby PD. Pathogenesis and treatment of Clostridium difficile infection. Postgrad Med J. 2005;81:367–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Poxton IR, McCoubrey J, Blair G. The pathogenicity of Clostridium difficile. Clin Microbiol Infect. 2001;7:421–7.

    Article  CAS  PubMed  Google Scholar 

  22. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol. 2010;31:431–55.

    Article  PubMed  Google Scholar 

  23. Surawicz CM, Brandt LJ, Binion DG, et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol. 2013;108:478–98. quiz 499

    Article  CAS  PubMed  Google Scholar 

  24. Carroll KC. Tests for the diagnosis of Clostridium difficile infection: the next generation. Anaerobe. 2011;17:170–4.

    Article  CAS  PubMed  Google Scholar 

  25. Reddymasu S, Sheth A, Banks DE. Is fecal leukocyte test a good predictor of Clostridium difficile associated diarrhea? Ann Clin Microbiol Antimicrob. 2006;5:9.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Khanna S, Pardi DS, Rosenblatt JE, Patel R, Kammer PP, Baddour LM. An evaluation of repeat stool testing for Clostridium difficile infection by polymerase chain reaction. J Clin Gastroenterol. 2012;46:846–9.

    Article  PubMed  Google Scholar 

  27. Shivashankar R, Khanna S, Kammer PP, et al. Clinical factors associated with development of severe-complicated Clostridium difficile infection. Clin Gastroenterol Hepatol. 2013;11:1466–71.

    Article  PubMed  Google Scholar 

  28. Orenstein R, Aronhalt KC, McManus JE Jr, Fedraw LA. A targeted strategy to wipe out Clostridium difficile. Infect Control Hosp Epidemiol. 2011;32:1137–9.

  29. Kelly CP, LaMont JT. Clostridium difficile—more difficult than ever. N Engl J Med. 2008;359:1932–40.

    Article  CAS  PubMed  Google Scholar 

  30. Dubberke ER, Gerding DN, Classen D, et al. Strategies to prevent Clostridium difficile infections in acute care hospitals. Infect Control Hosp Epidemiol. 2008;29 Suppl 1:S81–92.

  31. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis. 2007;45:302–7.

    Article  CAS  PubMed  Google Scholar 

  32. Johnson S, Louie TJ, Gerding DN, et al. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials. Clin Infect Dis. 2014;59:345–54.

    Article  CAS  PubMed  Google Scholar 

  33. Musher DM, Aslam S, Logan N, et al. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis. 2005;40:1586–90.

    Article  CAS  PubMed  Google Scholar 

  34. Pépin J, Valiquette L, Alary ME, et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ. 2004;171:466–72.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Gerber M, Ackermann G. OPT-80, a macrocyclic antimicrobial agent for the treatment of Clostridium difficile infections: a review. Expert Opin Investig Drugs. 2008;17:547–53.

    Article  CAS  PubMed  Google Scholar 

  36. Finegold SM, Molitoris D, Vaisanen ML, Song Y, Liu C, Bolaños M. In vitro activities of OPT-80 and comparator drugs against intestinal bacteria. Antimicrob Agents Chemother. 2004;48:4898–902.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Cornely OA, Crook DW, Esposito R, et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis. 2012;12:281–9.

    Article  CAS  PubMed  Google Scholar 

  38. Louie TJ, Miller MA, Mullane KM, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med. 2011;364:422–31.

    Article  CAS  PubMed  Google Scholar 

  39. Cornely OA, Nathwani D, Ivanescu C, Odufowora-Sita O, Retsa P, Odeyemi IA. Clinical efficacy of fidaxomicin compared with vancomycin and metronidazole in Clostridium difficile infections: a meta-analysis and indirect treatment comparison. J Antimicrob Chemother. 2014;69:2892–900.

    Article  CAS  PubMed  Google Scholar 

  40. Mullane KM, Miller MA, Weiss K, et al. Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections. Clin Infect Dis. 2011;53:440–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Lancaster JW, Matthews SJ. Fidaxomicin: the newest addition to the armamentarium against Clostridium difficile infections. Clin Ther. 2012;34:1–13.

    Article  CAS  PubMed  Google Scholar 

  42. Nathwani D, Cornely OA, Van Engen AK, Odufowora-Sita O, Retsa P, Odeyemi IA. Cost-effectiveness analysis of fidaxomicin versus vancomycin in Clostridium difficile infection. J Antimicrob Chemother. 2014;69:2901–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Khanna S, Pardi DS. Clostridium difficile infection: management strategies for a difficult disease. Therap Adv Gastroenterol. 2014;7:72–86.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Garey KW, Ghantoji SS, Shah DN, et al. A randomized, double-blind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection. J Antimicrob Chemother. 2011;66:2850–5.

    Article  CAS  PubMed  Google Scholar 

  45. Mattila E, Arkkila P, Mattila PS, Tarkka E, Tissari P, Anttila VJ. Rifaximin in the treatment of recurrent Clostridium difficile infection. Aliment Pharmacol Ther. 2013;37:122–8.

    Article  CAS  PubMed  Google Scholar 

  46. White CA Jr. Nitazoxanide: a new broad spectrum antiparasitic agent. Expert Rev Anti-Infect Ther. 2004;2:43–9.

  47. Musher DM, Logan N, Bressler AM, Johnson DP, Rossignol JF. Nitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double-blind study. Clin Infect Dis. 2009;48:e41–6.

    Article  CAS  PubMed  Google Scholar 

  48. Locher HH, Caspers P, Bruyère T, et al. Investigations of the mode of action and resistance development of cadazolid, a new antibiotic for treatment of Clostridium difficile infections. Antimicrob Agents Chemother. 2014;58:901–8.

    Article  PubMed  PubMed Central  Google Scholar 

  49. Baldoni D, Gutierrez M, Timmer W, Dingemanse J. Cadazolid, a novel antibiotic with potent activity against Clostridium difficile: safety, tolerability and pharmacokinetics in healthy subjects following single and multiple oral doses. J Antimicrob Chemother. 2014;69:706–14.

    Article  CAS  PubMed  Google Scholar 

  50. Louie T, Nord CE, Talbot GH, et al. Multicenter, double-blind, randomized, phase 2 study evaluating the novel antibiotic cadazolid in patients with Clostridium difficile infection. Antimicrob Agents Chemother. 2015;59:6266–73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Mascio CT, Chesnel L, Thorne G, Silverman JA. Surotomycin demonstrates low in vitro frequency of resistance and rapid bactericidal activity in Clostridium Difficile, Enterococcus faecalis, and Enterococcus faecium. Antimicrob Agents Chemother. 2014;58:3976–82.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Knight-Connoni V, Mascio C, Chesnel L, Silverman J. Discovery and development of surotomycin for the treatment of Clostridium difficile. J Ind Microbiol Biotechnol. 2016;43:195–204.

    Article  CAS  PubMed  Google Scholar 

  53. Lee CH, Patino H, Stevens C, et al. Surotomycin versus vancomycin for Clostridium difficile infection: phase 2, randomized, controlled, double-blind, non-inferiority, multicentre trial. J Antimicrob Chemother. 2016;71:2964–71.

    Article  CAS  PubMed  Google Scholar 

  54. Vickers RJ. Ridinilazole for Clostridium difficile infections: safety and efficacy compared with vancomycin from the CoDIFy phase 2 trial. European Society of Clinical Microbiology and Infectious Diseases (ECCMID) 2016, 2016

  55. Chang J, et al.Ridinilazole preserves major components of the intestinal microbiota during treatment of clostridium difficile infection. American Society for Microbiology (ASM) Microbe 2016, 2016

  56. Allen SJ, Wareham K, Wang D, et al. Lactobacilli and Bifidobacteria in the prevention of antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in older inpatients (PLACIDE): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2013;382:1249–57.

    Article  PubMed  Google Scholar 

  57. Hempel S, Newberry SJ, Maher AR, et al. Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis. JAMA. 2012;307:1959–69.

    Article  CAS  PubMed  Google Scholar 

  58. Ritchie ML, Romanuk TN. A meta-analysis of probiotic efficacy for gastrointestinal diseases. PLoS One. 2012;7:e34938.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Pillai A, Nelson R. Probiotics for treatment of Clostridium difficile-associated colitis in adults. Cochrane Database Syst Rev. 2008;CD004611

  60. Johnston BC, Ma SS, Goldenberg JZ, et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea: a systematic review and meta-analysis. Ann Intern Med. 2012;157:878–88.

    Article  PubMed  Google Scholar 

  61. McFarland LV. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am J Gastroenterol. 2006;101:812–22.

    Article  PubMed  Google Scholar 

  62. Kreutzer EW, Milligan FD. Treatment of antibiotic-associated pseudomembranous colitis with cholestyramine resin. Johns Hopkins Med J. 1978;143:67–72.

    CAS  PubMed  Google Scholar 

  63. Kassam Z, Lee CH, Yuan Y, Hunt RH. Fecal microbiota transplantation for Clostridium difficile infection: systematic review and meta-analysis. Am J Gastroenterol. 2013;108:500–8.

    Article  PubMed  Google Scholar 

  64. Hu MY, Katchar K, Kyne L, et al. Prospective derivation and validation of a clinical prediction rule for recurrent Clostridium difficile infection. Gastroenterology. 2009;136:1206–14.

    Article  PubMed  Google Scholar 

  65. van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013;368:407–15.

    Article  PubMed  Google Scholar 

  66. Drekonja D, Reich J, Gezahegn S, et al. Fecal microbiota transplantation for Clostridium difficile infection: a systematic review. Ann Intern Med. 2015;162:630–8.

    Article  PubMed  Google Scholar 

  67. Kelly CR, Ihunnah C, Fischer M, et al. Fecal microbiota transplant for treatment of Clostridium difficile infection in immunocompromised patients. Am J Gastroenterol. 2014;109:1065–71.

    Article  PubMed  Google Scholar 

  68. Brandt LJ, Aroniadis OC, Mellow M, et al. Long-term follow-up of colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection. Am J Gastroenterol. 2012;107:1079–87.

    Article  PubMed  Google Scholar 

  69. Tariq R, Smyrk T, Pardi DS, Tremaine WJ, Khanna S. New-onset microscopic colitis in an ulcerative colitis patient after fecal microbiota transplantation. Am J Gastroenterol. 2016;111:751–2.

    Article  PubMed  Google Scholar 

  70. De Leon LM, Watson JB, Kelly CR. Transient flare of ulcerative colitis after fecal microbiota transplantation for recurrent Clostridium difficile infection. Clin Gastroenterol Hepatol. 2013;11:1036–8.

    Article  PubMed  Google Scholar 

  71. Quera R, Espinoza R, Estay C, Rivera D. Bacteremia as an adverse event of fecal microbiota transplantation in a patient with Crohn’s disease and recurrent Clostridium difficile infection. J Crohns Colitis. 2014;8:252–3.

    Article  PubMed  Google Scholar 

  72. Alang N, Kelly CR. Weight gain after fecal microbiota transplantation. Open Forum Infect Dis. 2015;2:ofv004.

    Article  PubMed  PubMed Central  Google Scholar 

  73. Paramsothy S, Borody TJ, Lin E, et al. Donor recruitment for fecal microbiota transplantation. Inflamm Bowel Dis. 2015;21:1600–6.

    Article  PubMed  Google Scholar 

  74. Youngster I, Russell GH, Pindar C, Ziv-Baran T, Sauk J, Hohmann EL. Oral, capsulized, frozen fecal microbiota transplantation for relapsing Clostridium difficile infection. JAMA. 2014;312:1772–8.

    Article  CAS  PubMed  Google Scholar 

  75. Gerding DN, Meyer T, Lee C, et al. Administration of spores of nontoxigenic Clostridium difficile strain M3 for prevention of recurrent C. difficile infection: a randomized clinical trial. JAMA. 2015;313:1719–27.

    Article  PubMed  Google Scholar 

  76. Orenstein R, Dubberke E, Hardi R, et al. Safety and durability of RBX2660 (microbiota suspension) for recurrent Clostridium difficile infection: results of the PUNCH CD study. Clin Infect Dis. 2016;62:596–602.

    Article  PubMed  Google Scholar 

  77. Khanna S, Pardi DS, Kelly CR, et al. A novel microbiome therapeutic increases gut microbial diversity and prevents recurrent Clostridium difficile infection. J Infect Dis. 2016;214:173–81.

    Article  PubMed  Google Scholar 

  78. Aboudola S, Kotloff KL, Kyne L, et al. Clostridium difficile vaccine and serum immunoglobulin G antibody response to toxin A. Infect Immun. 2003;71:1608–10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  79. Lowy I, Molrine DC, Leav BA, et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med. 2010;362:197–205.

    Article  CAS  PubMed  Google Scholar 

  80. Wilcox M. Bezlotoxumab alone and with actoxumab for prevention of recurrent Clostridium difficile infection in patients on standard of care antibiotics: integrated results of 2 phase 3 studies (MODIFY I and MODIFY II). Open Forum Infectious Diseases, 2015. 2 Suppl 1: 67

  81. Kelly CP, et al. The monoclonal antibody, bezlotoxumab targeting C. difficile toxin B shows efficacy in preventing recurrent C. difficile infection (CDI) in patients at high risk of recurrence or of CDI-related adverse outcomes. Gastroenterology, 2016;150:4 Suppl. 1: p. S122

Download references

Author information

Authors and Affiliations

  1. Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA

    Raseen Tariq & Sahil Khanna

Authors
  1. Raseen Tariq
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sahil Khanna
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sahil Khanna.

Ethics declarations

Conflict of interest

Sahil Khanna serves as a consultant to Rebiotix Inc. for Clostridium difficile infection-related studies.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tariq, R., Khanna, S. Clostridium difficile infection: Updates in management. Indian J Gastroenterol 36, 3–10 (2017). https://doi.org/10.1007/s12664-016-0719-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12664-016-0719-z

Keywords

Search

Navigation